We want leading pharmaceutical companies to spearhead the advancement of this new alternative to biological indicators and reap the benefits. Enzyme Indicators represent a multi-million pound investment – currently protected globally by in excess of sixty patents and supported by Public Health England. We offer a try before you buy period where pharmaceutical companies can trial EIs alongside traditional biological indicators for their decontamination validation processes – put them head to head and see what you are missing out on. This trial period ensures you gain invaluable insight into both the accurancy and speed of this new science. We offer full training and certification and can help you utilise the quantifiable data in the best ways for your business. Financial Directors will see the savings to be made in man-hours, by avoiding product recalls and by providing instant assured product release. Quality Directors will finally be offered complete assurance and peace-of-mind, satisfied that the process is continually monitored and verified, in real time. This quantifiable data with pre-emptive knowledge can provide an early warning allowing Quality teams to be pro-active, rather than re-active to ensure the right decontamination results. Try before you buy and reap the rewards of this revolutionary new science.